Skip to content
Vfend(voriconazole)
Vfend (voriconazole) is a small molecule pharmaceutical. Voriconazole was first approved as Vfend on 2002-03-19. It is used to treat aspergillosis, candidiasis, fusariosis, and mycoses in the USA. It has been approved in Europe to treat aspergillosis, bacterial infections and mycoses, candidiasis, and mycoses.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Vfend (generic drugs available since 2010-04-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Voriconazole
Tradename
Company
Number
Date
Products
VFENDCV SciencesN-021266 RX2002-05-24
2 products, RLD, RS
VFENDCV SciencesN-021267 RX2002-05-24
1 products, RLD, RS
VFENDCV SciencesN-021630 RX2003-12-19
1 products, RLD, RS
VORICONAZOLEXelliaN-208562 RX2017-03-09
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
vfendNew Drug Application2022-12-22
voriconazoleNew Drug Application2023-04-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aspergillosisEFO_0007157D001228B44
candidiasisD002177B37
fusariosisEFO_1001795D060585
mycosesD009181B35-B49
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J02: Antimycotics for systemic use
J02A: Antimycotics for systemic use
J02AC: Triazole and tetrazole derivatives
J02AC03: Voriconazole
HCPCS
Code
Description
J3465
Injection, voriconazole, 10 mg
Clinical
Clinical Trials
127 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B4961103524
AspergillosisD001228EFO_0007157B44257417
Healthy volunteers/patients8311
Invasive pulmonary aspergillosisD055744B44.0123129
Invasive fungal infectionsD0000727422349
CandidiasisD002177B3721227
InfectionsD007239EFO_00005442215
CandidemiaD058387EFO_10012821124
Invasive candidiasisD058365EFO_1001283B37213
Invasive hydatidiform moleD002820D39.2112
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.02314
LeukemiaD007938C951214
Corneal ulcerD003320H16.0134
NeutropeniaD009503D701213
Hiv infectionsD015658EFO_0000764B20112
LymphomaD008223C85.9112
Allergic bronchopulmonary aspergillosisD001229EFO_0007140B44.811112
Fungal eye infectionsD01582122
Hematologic neoplasmsD0193371112
NeuroaspergillosisD020953EFO_000739311
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D461314
NeoplasmsD009369C80213
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0111
Myelomonocytic leukemia chronicD015477C93.1111
Tinea versicolorD014010EFO_0007439B36.011
PainD010146EFO_0003843R5211
HyperalgesiaD00693011
BurnsD002056T30.011
FusariumD00567011
Immunocompromised hostD016867D84.911
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.81213
Stem cell transplantationD03358122
Hiv-1D01549711
Bacterial infectionsD001424A4911
AsthmaD001249EFO_0000270J4511
AnesthesiaD00075811
Cryptococcal meningitisD016919EFO_0007228B45.111
B-cell chronic lymphocytic leukemiaD015451C91.111
Microbial drug resistanceD00435211
Photothermal therapyD00008270311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.722
Multiple myelomaD009101C90.011
Hematologic diseasesD006402EFO_0005803D75.911
Hematopoietic stem cell transplantationD01838011
Bone marrow transplantationD01602611
FusariosisD060585EFO_100179511
OnychomycosisD014009B35.111
TherapeuticsD01381211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVORICONAZOLE
INNvoriconazole
Description
Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a member of pyrimidines, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug.
Classification
Small molecule
Drug classsystemic antifungals (miconazole type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
Identifiers
PDB
CAS-ID137234-62-9
RxCUI121243
ChEMBL IDCHEMBL638
ChEBI ID10023
PubChem CID71616
DrugBankDB00582
UNII IDJFU09I87TR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000638805CYP2C19, Gly91Argdrug response2019-06-17P
VCV000638804CYP2C19, His78Tyrdrug response2019-06-17P
VCV000638803CYP2C19, Arg73Cysdrug response2019-06-17P
VCV000638802CYP2C19, Arg442Cysdrug response2019-06-17P
VCV000638801CYP2C19, Ser51Glydrug response2019-06-17P
VCV000638800CYP2C19, Asp256Asndrug response2019-06-17P
VCV000638799CYP2C19, Ile19Leudrug response2019-06-17P
VCV000638798CYP2C19, Lys399=, Arg335Glndrug response2019-06-17P
VCV000638797CYP2C19, Pro227=drug response2019-06-17P
VCV000638796CYP2C19, Arg410Cysdrug response2019-06-17P
Show 585 more
Financial
Vfend - Pfizer
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 17,576 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
59 adverse events reported
View more details